MedTrace Logo

Acute Renal Failure Post Liver Transplantation

NCT01907061 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-02-21

No results posted yet for this study

Summary

Trial to test the effect of administering N-acetylcysteine on cytokines and markers of oxidant stress and the incidence of acute renal failure post liver tranplant

Conditions

  • Acute Renal Failure

Interventions

DRUG

N-acetylcysteine

drug will be administered via IV,NG

DRUG

Placebo

placebo or NAC will be given

Sponsors & Collaborators

  • Baylor Research Institute

    lead OTHER

Principal Investigators

  • Yousri M. Barri, MD · Baylor Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
71 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01907061 on ClinicalTrials.gov